Check Point Software Technologies (NASDAQ:CHKP) reported better-than-expected earnings for the consecutive straight quarter, primarily due to strong subscription sales and introduction of innovative security solutions for the cloud, mobile and advanced threat prevention.
It last posted its earnings for Q12017 on April 27th. The company reported EPS of $1.20 for the quarter, topping Street estimates of $1.19 by $0.01. The company had revenue of $435 million for the quarter compared to the Street estimate of $432 million. During the same quarter in the prior year, the company posted adjusted EPS of $1.06. Currently, analysts expect CHKP to generate revenue of $454 million and EPS of $1.23 in Q22017. CHKP has a 12-month low of $74.34 and a 12-month high of $106.38 (CMP $105). The firm’s market cap is $17.55 billion.
Best High Tech Stocks To Own Right Now: Mitsubishi UFJ Financial Group Inc(MTU)
- [By Jim Jubak, Senior Markets Editor, MoneyShow.com]
The one currency that is running against the weak dollar tide is the Japanese yen. The yen initially climbed on the Fed’s no taper decision—rising to 97.75 on the news—but then fell all the way back to 99 yen to the dollar and finished yesterday at 99.42. (Remember that since the yen is quoted in yen to the dollar, a higher number is a sign of a weak yen and a smaller number means the yen is getting stronger.) The thinking seems to be that the recent Japanese trade deficit will push the Bank of Japan to further weaken the yen, in order to boost Japanese exports. I continue to think that the yen will finish 2013 at weaker levels than current trading, and that leads me to continue to hold positions in Japanese stocks such as Toyota Motor (TM) and Mitsubishi UFJ Financial Group (MTU). Both stocks are members of my Jubaks Picks portfolio.
Best High Tech Stocks To Own Right Now: (SIOLF)
- [By SEEKINGALPHA.COM]
China Life (NYSE:LFC) holds a 44 percent stake in China Guangfa Bank and a 30 percent stake in Sino-Ocean Group (OTCPK:SIOLF). Foresea owns large stakes in Gree Electric Appliances and China Vanke. If they are forced to sell their stakes, the Chinese stock market could see a sudden downturn.
Best High Tech Stocks To Own Right Now: Eli Lilly and Company(LLY)
- [By David Zeiler]
Pharma stocks shot up in the wake of Donald Trump’s victory. Eli Lilly and Co. (NYSE: LLY) and Merck & Co. (NYSE: MRK) both rose about 6%, while Pfizer Inc. (NYSE: PFE) jumped 7%.
- [By WWW.THESTREET.COM]
Bond prices were much lower early in the day, with yields up by nearly 10 basis points. But fixed income has rallied back (reducing the drop by half on the day). Valeant Pharmaceuticals (VRX) , more weakness. Large pharma lower, led by Eli Lilly (LLY) . Old tech lags, with International Business Machines (IBM) , Intel (INTC) , Cisco Systems (CSCO) and Microsoft (MSFT) all lower. Media roughed up a bit (CBS (CBS) and Comcast (CMCSA) ). The Ugly
Gold down another $23 to $1,188 (SPDR Gold Trust ETF (GLD) down $2.25). Urban Outfitters (URBN) down $5. NOTE: There will be no “Takeaways” today! Happy Thanksgiving. Position: Long GLD small, SDS large, JCP large; short SPY, CSCO, CAT small, IWM, TLT small.
- [By WWW.THESTREET.COM]
Cramer recalled recently investing in Eli Lilly (LLY) on hopes the company’s Alzheimer’s research would be worth billions. As time has worn on, Lilly’s obstacles to success seem to be mounting. Not knowing if or when Lilly might see success, Cramer said he sold the stock and moved on.
- [By WWW.THESTREET.COM]
That’s why Cramer said he’d use today’s weakness to buy Merck (MRK) , Eli Lilly (LLY) , Pfizer (PFE) and Allergan (AGN) , an Action Alerts PLUS holding.
- [By Dimitra DeFotis]
Shares of Eli Lilly (LLY) are down nearly 13% this morning after a late-stage Alzheimer’s drug trial failed to produce expected results.
Biogen(BIIB), down nearly 6% today, also is working on an Alzheimer’s treatment; Merck (MRK) shareswere down 1% in recent trading.
Lilly was testing the drug as a treatment for mild dementia due to Alzheimer’s disease.Credit Suisse analysts were hopeful the drug trial would show “a statistically significant impact on cognition.”MarketWatch reports:
“Eli Lilly said it would not pursue approval for the drug to treat mild dementia due to Alzheimers disease and that it will ‘evaluate the impact of these results on the development plans for solanezumab and our other Alzheimers pipeline assets’ … More specifics about the solanezumab drug, expected the night of Dec. 9 during a meeting of the Clinical Trials on Alzheimers Disease (CTAD), could have repercussions for whats called the beta amyloid hypothesis in Alzheimers disease treatments, which target protein fragments that some believe are responsible for the disease …”
On Nov. 15, J.P. Morgan analysts Chris Schott, Aditi Singhania, Dana Flanders and Christopher Neyor noted that trial success had a low probability. But they kept their$95 price target on the stock, noting the drug pipeline offers other opportunities. Their target implies upside of more than 40% from a recent price near $66. They wrote:
“… On solanezumab … While the FDA recommends both cognitive and function endpoints for Alzheimers drug approvals, we expect the agency to review solanezumab on the totality of evidence, and we would not be surprised to see a cognitive benefit coupled with a trend in secondary functional endpoints be sufficient for approval … regardless of the solanezumab outcome, we see a diverse range of new product opportunities supporting LLY
- [By Keith Speights]
With this rapidly growing market, there are plenty of opportunities for investors. Zoetis (NYSE:ZTS), Merck (NYSE:MRK), and Eli Lilly (NYSE:LLY) stand out as the top animal-health companies to buy in 2017. Here’s why.